Fatigue is a common problem in MS, which affects as many as 90% of patients. The cause of fatigue in patients is thought to be down to a number of factors, especially genetic or environmental. There is also some evidence that ongoing central nervous system (CNS) inflammation is a contributing factor. AHSCT have been shown to halt ongoing CNS inflammation.
Researchers set out to discover whether halting all ongoing inflammation with AHSCT impacts fatigue scores in patients with severe MS.
In the Canadian AHSCT study, 23 patients underwent AHSCT and had their fatigue impact scale (FIS) scores prospectively collected every six months for 36 months of follow-up.
The median FIS score decreased 36%, from 36 to 23, and four patients had 100% reduction. Improvement in FIS correlated with lower age and Expanded Disability Status Scale at baseline, as well as increased independence as evidenced by a return to gainful employment and even driving.
The researchers concluded that patients experience significantly less fatigue on average after AHSCT. This may serve to better understand the contribution of ongoing CNS inflammation to fatigue peculiar to MS.
Source MS-UK 04/10/2018